High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Abstract Background As older age and having certain comorbidities can influence humoral responses to vaccination, we studied antibody responses after the COVID-19 booster campaigns in nursing home (NH) residents. Methods In a two year longitudinal study with Dutch NH residents (n = 107), aged 50 yea...
Saved in:
Main Authors: | Marloes I Hofstee, Joanna Kaczorowska, Abigail Postema, Erna Zomer, Maren van Waalwijk, Gustaaf Jonathans, Lia GH de Rond, Gaby Smits, Lotus L van den Hoogen, Gerco den Hartog, Anne-Marie Buisman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Immunity & Ageing |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12979-024-00495-4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01) -
Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01) -
Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platformResearch in context
by: Jennifer L. Nguyen, et al.
Published: (2025-01-01) -
BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura
by: A. K. Ghosh, et al.
Published: (2022-01-01) -
TLR Agonist Immunoadjuvants Provide Effective Protection Against PCV2 and PRV Infections in a Bivalent Subunit Vaccine for PCV2 and PRV
by: Fulai Yu, et al.
Published: (2025-01-01)